Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Advances in chemotherapy for small cell lung cancer: Single-agent activityof newer agents
Autore:
Argiris, A; Murren, JR;
Indirizzi:
Northwestern Univ, Sch Med, Chicago, IL 60611 USA Northwestern Univ Chicago IL USA 60611 iv, Sch Med, Chicago, IL 60611 USA Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA Robert H Lurie Comprehens Canc Ctr Chicago IL USA c Ctr, Chicago, IL USA Yale Univ, Sch Med, New Haven, CT USA Yale Univ New Haven CT USAYale Univ, Sch Med, New Haven, CT USA Yale Canc Ctr, New Haven, CT USA Yale Canc Ctr New Haven CT USAYale Canc Ctr, New Haven, CT USA
Titolo Testata:
CANCER JOURNAL
fascicolo: 3, volume: 7, anno: 2001,
pagine: 228 - 235
SICI:
1528-9117(200105/06)7:3<228:AICFSC>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-II TRIAL; PREVIOUSLY UNTREATED PATIENTS; ANAPLASTIC BRONCHOGENIC-CARCINOMA; COOPERATIVE-ONCOLOGY-GROUP; PREVIOUSLY TREATED PATIENTS; HIGH-DOSE EPIRUBICIN; LONG-TERM SURVIVAL; RANDOMIZED TRIAL; ORAL ETOPOSIDE; COMBINATION CHEMOTHERAPY;
Keywords:
small cell lung cancer; chemotherapy;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
85
Recensione:
Indirizzi per estratti:
Indirizzo: Argiris, A Northwestern Univ, Sch Med, 676 N St Clair St, Chicago, IL 60611 USA Northwestern Univ 676 N St Clair St Chicago IL USA 60611 11 USA
Citazione:
A. Argiris e J.R. Murren, "Advances in chemotherapy for small cell lung cancer: Single-agent activityof newer agents", CANCER J, 7(3), 2001, pp. 228-235

Abstract

Small cell lung cancer (SCLC) is a common neoplasm with an extremely poor prognosis. Patients with extensive-stage disease have a 5-year survival rate of 1% to 2%. Identification of new active chemotherapy agents is of greatimportance for the development of more effective treatment for SCLC. Several new drugs that have established a role in the management of non-SCLC in the past decade are also active in SCLC. The mean response rates in untreated versus previously treated patients for these newer drugs are: 26% versus14% for vinorelbine, 27% versus 14% for gemcitabine, 45% versus 29% for paclitaxel, 22% versus 25% for docetaxel, 39% versus 19% for topotecan, and 50% versus 16% to 24% for irinotecan. A comparison of the response rates of those agents to more established drugs (e.g., cisplatin and etoposide) suggests that the newer drugs are equally or more active in previously treated patients with SCLC. This activity is even more impressive because initial therapy during the past decade has almost always included platinum and/or anepipodophyllotoxin in the regimen. Furthermore, a recent randomized trial showed that the combination of a newer agent (irinotecan) with cisplatin was superior to a standard etoposide and cisplatin regimen in patients with newly diagnosed extensive-stage SCLC. These data support further evaluation of the newer chemotherapeutic drugs, and especially the camptothecins (irinotecan and topotecan) and the taxanes (paclitaxel and docetaxel), in the initial treatment of SCLC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/02/20 alle ore 20:41:36